Insertions/Deletions in the Antithrombin Gene: 3 Mutations Associated with Non-Expression

Summary

We have investigated the molecular basis of antithrombin deficiency in 3 individuals, 2 of whom had a proven family history of thromboembolic disease. An approximate 50% reduction in functional and immunologic levels of antithrombin was detected in plasma from the propositi indicating an allelic deficiency of antithrombin. In each case direct sequencing of amplified DNA revealed a novel mutation involving single bases: two being insertions, of a T in codon 48 and an A in codon 208, and the third being the deletion of an A in codon 370. The three mutations, which were confirmed by cloning and sequencing the normal and variant alleles, all caused frameshifts leading to premature termination of protein translation. In no case could a truncated antithrombin be detected in plasma from the propositus suggesting either that it fails to be secreted, or is rapidly degraded.

• References

• 1 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
• 2 Petersen TE, Dudek-Wojciechowska G, Sottrup-Jensen L, Magnus-son S. Primary structure of antithrombin III (heparin cofactor). Partial homology between al-antitrypsin and antithrombin III. In: Physiological Inhibitors of Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds) Elsevier/North-Holland; Amsterdam: 1979. p 43
• 3 Lane DA, Caso R. Antithrombin: structure, genomic organisation, functional and inherited deficiency. Bailliere’s Clin Haematol 1989; 2: 961-997
• 4 Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin: A database of mutations. Thromb Haemostas 1991; 66: 657-661
• 5 Bock SC, Silbermann JA, Wikoff W, Abildgaard U, Hultin MB. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemostas 1989; 62: 494
• 6 Tait RC, Walker ID, Perry DJ, Carrell RW, Islam SIA, Mitchell R, Davidson JF. Prevalence of antithrombin III deficiency subtypes in 4,000 healthy blood donors. Thromb Haemostas 1991; 65: 839
• 7 Scharrer I, Hach-Wunderle H, Aygoren E. Prevalence of inherited thrombophilia in 800 juvenile patients with DVT and/or PE in the Frankfurt area. In: Abstract Book, Xth International Congress on Thrombosis of the Mediterranean League against Thromboembolic Disease, Athens. Michalopoulos CD. (ed). p 70
• 8 Briet E, Engesser L, Brommer EJP. The prevalence of familial thrombophilia. In: Abstract Book, Xth International Congress of Thrombosis of the Mediterranean League against Thromboembolic Disease, Athens. Michalopoulos CD. (ed). p 69
• 9 Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, Perry DJ, Carrell RW. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991; 77: 360-364
• 10 Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III gene to chromosome lq23-25. Cytogenet Cell Genet 1985; 39: 67-69
• 11 Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: Proline 407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27: 6171-6178
• 12 Bock SC, Prochownik EV. Molecular genetic survey of 16 kindreds with hereditary antithrombin III deficiency. Blood 1987; 70: 1273-1278
• 13 Olds RJ, Lane DA, Finazzi G, Barbui T, Thein S-L. A frameshift mutation leading to type I antithrombin deficiency and thrombosis. Blood 1990; 76: 2182-2186
• 14 Olds RJ, Lane DA, Ireland H, Leone G, De Stefano V, Wiesel ML, Cazenave J-P, Thein SL. Novel point mutations leading to type I antithrombin deficiency and thrombosis. Br J Haematol 1991; 78: 408-413
• 15 Gandrille S, Vidaud D, Emmerich J, Clauser E, Sie P, Fiessinger JN, Alhenc-Gelas M, Priollet P, Aiach M. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon in exon Ilia and a frameshift in exon XI. Br J Haematol 1991; 78: 414-420
• 16 Edgar P, Jennings I, Harper P. Enzyme-linked immunosorbent assay for measuring AT III. J Clin Pathol 1989; 42: 985-987
• 17 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 125 (suppl) 21-37
• 18 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrate (S2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
• 19 Harper P, Daly M, Price J, Edgar PF, Carrell RW. Screening for heparin binding variants of antithrombin. J Clin Pathol 1991; 44: 477-479
• 20 Perry DJ, Harper PL, Fairham S, Daly M, Carrell RW. Antithrombin Cambridge, 384 Ala to Pro: a new variant identified using the polymerase chain reaction. FEBS Lett 1989; 254: 174-176
• 21 Daly M, Perry DJ. Dde I polymorphism in intron 5 of the ATIII gene. Nucl Acids Res 1990; 18: 5583
• 22 Daly M, Bruce D, Perry DJ, Price J, Harper PL, O’Meara A, Carrell RW. Antithrombin Dublin (-3 Val —» Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett 1990; 273: 87-90
• 23 Gyllensten U. Direct sequencing of in vitro amplified DNA. In: PCR Technology, Principles and Applications for DNA Amplification. Erlich HA. (ed) Stockton Press; New York, London: 1989. pp 45-60
• 24 Newton CR, Kalsheker N, Graham A, Gammack A, Riley J, Markham AF. Diagnosis of al-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucl Acids Res 1988; 16: 8233-8243
• 25 Miller H. Practical Aspects of Preparing Phage and Plasmid DNA: Growth, Maintenance, and Storage of Bacteria and Bacteriophage. In: Methods in Enzymology, Vol 152: Guide to Molecular Cloning Techniques. Berger SL, Kimmel AR. (Eds) Academic Press; New York, London: 1987. pp 145-170
• 26 Daly M, O’Meara A, Hallinan F. Identification and characterisation of a new antithrombin III familial variant (AT Dublin) with possible increased frequency in children with cancer. Br J Haematol 1987; 65: 457-462